Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome

ABSTRACT Irritable bowel syndrome (IBS) is a common disorder of the lower gastrointestinal tract. The pathophysiology is far from settled, but a gut microbial dysbiosis is hypothesized to be a contributing factor. We earlier published a randomized double-blind placebo-controlled clinical trial on fecal microbiota transplantation (FMT) for IBS – the REFIT trial. The present data set describes the engraftment and includes participants from the study who received active FMT; 14 participants with effect of FMT (Effect) and 8 without (No effect). Samples were collected at baseline, after 6 and 12 months. Samples from the transplants (Donor) served as a comparator. In total 66 recipient samples and 17 donor samples were subjected to deep metagenomic sequencing, and taxonomic and functional analyses were performed. Alpha diversity measures showed a significantly increased diversity and evenness in the IBS groups compared to the donors. Taxonomic profiles showed higher relative abundance of phylum Firmicutes, and lower relative abundance of phylum Bacteroidetes, compared to donors at baseline. This profile was shifted toward the donor profile following FMT. Imputed growth rates showed that the resulting growth pattern was a conglomerate of donor and recipient activity. Thirty-four functional subclasses showed distinct differences between baseline samples and donors, most of which were shifted toward a donor-like profile after FMT. All of these changes were less pronounced in the No effect group. We conclude that FMT induces long-term changes in gut microbiota, and these changes mirror the clinical effect of the treatment. The study was registered in ClinicalTrials.gov (NCT02154867).

[1]  L. Engstrand,et al.  No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population , 2019, Gut.

[2]  M. Schmulson,et al.  Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis , 2019, United European gastroenterology journal.

[3]  M. Ciccozzi,et al.  Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease , 2019, Front. Microbiol..

[4]  M. Surette,et al.  Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. , 2019, Gastroenterology.

[5]  D. Plichta,et al.  Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis , 2019, Science.

[6]  L. Duan,et al.  Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome , 2019, Chinese medical journal.

[7]  K. Faber,et al.  Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases , 2019, Front. Immunol..

[8]  T. Spector,et al.  Interplay between the human gut microbiome and host metabolism , 2019, Nature Communications.

[9]  L. Duan,et al.  Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review , 2019, Clinical and translational gastroenterology.

[10]  Morris A. Swertz,et al.  Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome , 2018, Science Translational Medicine.

[11]  D. Busch,et al.  An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila , 2018, Digestion.

[12]  C. Dejaco,et al.  Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy , 2018, International journal of molecular sciences.

[13]  Julia Oh,et al.  High throughput in situ metagenomic measurement of bacterial replication at ultra-low sequencing coverage , 2018, Nature Communications.

[14]  Simon Andrews,et al.  FastQ Screen: A tool for multi-genome mapping and quality control , 2018, F1000Research.

[15]  L. Hansen,et al.  Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study , 2018, Gut.

[16]  J. Clardy,et al.  Quinones are growth factors for the human gut microbiota , 2017, Microbiome.

[17]  K. Whelan,et al.  The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS , 2017, Gut.

[18]  N. Oezguen,et al.  Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome , 2017, Microbiome.

[19]  T. Hausken,et al.  Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  Jia Gu,et al.  AfterQC: automatic filtering, trimming, error removing and quality control for fastq data , 2017, BMC Bioinformatics.

[21]  E. Lionetti,et al.  The Low FODMAP Diet: Many Question Marks for a Catchy Acronym , 2017, Nutrients.

[22]  O. Ahmad,et al.  Microbiome, antibiotics and irritable bowel syndrome. , 2016, British medical bulletin.

[23]  Anders Krogh,et al.  Fast and sensitive taxonomic classification for metagenomics with Kaiju , 2016, Nature Communications.

[24]  Bas E. Dutilh,et al.  SUPER-FOCUS: a tool for agile functional analysis of shotgun metagenomic data , 2015, Bioinform..

[25]  James Kinross,et al.  The gut microbiota and host health: a new clinical frontier , 2015, Gut.

[26]  C. Manichanh,et al.  Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome , 2015, Scientific Reports.

[27]  R. Spiller,et al.  Irritable bowel syndrome , 2015, Nature Reviews Disease Primers.

[28]  L. Laine,et al.  Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. , 2015, Gastroenterology.

[29]  M. Camilleri.  Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  P. Savelkoul,et al.  The Effect of Sampling and Storage on the Fecal Microbiota Composition in Healthy and Diseased Subjects , 2015, PloS one.

[31]  L. Öhman,et al.  Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome , 2015, Gut and liver.

[32]  Chao Xie,et al.  Fast and sensitive protein alignment using DIAMOND , 2014, Nature Methods.

[33]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[34]  Robert G. Beiko,et al.  STAMP: statistical analysis of taxonomic and functional profiles , 2014, Bioinform..

[35]  Changjin Hong,et al.  PathoScope 2.0: a complete computational framework for strain identification in environmental or clinical sequencing samples , 2014, Microbiome.

[36]  C. Dozois,et al.  Iron, copper, zinc, and manganese transport and regulation in pathogenic Enterobacteria: correlations between strains, site of infection and the relative importance of the different metal transport systems for virulence , 2013, Front. Cell. Infect. Microbiol..

[37]  M. Martinussen,et al.  Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test , 2013, Scandinavian journal of gastroenterology.

[38]  Susan Holmes,et al.  phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data , 2013, PloS one.

[39]  M. Dapoigny,et al.  The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[40]  H. Gaskins,et al.  Microbial pathways in colonic sulfur metabolism and links with health and disease , 2012, Front. Physio..

[41]  E. Zoetendal,et al.  Intestinal microbiota in functional bowel disorders: a Rome foundation report , 2012, Gut.

[42]  S. Raimondi,et al.  Folate Production by Probiotic Bacteria , 2011, Nutrients.

[43]  P. Gibson,et al.  Evidence‐based dietary management of functional gastrointestinal symptoms: The FODMAP approach , 2010, Journal of gastroenterology and hepatology.

[44]  A. Ford,et al.  Irritable bowel syndrome , 2005, The New England journal of medicine.

[45]  G. Weiss,et al.  Role of divalent metals in infectious disease susceptibility and outcome. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[46]  D. Doman,et al.  Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis. , 2015, Gastroenterology & hepatology.

[47]  L. Laine,et al.  Update on FMT 2015: Indications, Methodologies, Mechanisms and Outlook , 2015 .